Physiomics Awarded New Contract

In brief · summary, not quotable

Physiomics plc has secured a new contract with a South Korean biopharmaceutical client, valued at up to £66,600, to provide PK/PD modelling and simulation services for a clinical-stage oncology asset. This project, which is expected to conclude within two months, highlights Physiomics' expansion into new international markets and its role in supporting drug development decisions.

Full announcement

Select text to share a quote on X · sign in to keep highlights & notes in your PYC notes

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce a contract award with a new biopharmaceutical client headquartered in South Korea.

This new project is with a South Korean clinical stage biopharmaceutical company focused on the development of next-generation antibody drug conjugate (ADC) and Immuno-oncology therapeutic for the treatment of cancer. Under the terms of the contract, Physiomics will use PK/PD modelling and simulation techniques to support dosing decisions for one of the client's clinical stage assets. The project, valued at up to £66,600, will commence immediately with completion anticipated within the next two months.

Dr Peter Sargent, CEO of Physiomics, commented:

"We are thrilled to have been selected to partner with this new South Korean client on their important clinical stage programme. This engagement underscores Physiomics' continued commitment to deliver robust quantitative insights that de-risk development strategies and enhance decision making, whilst reflecting the Company's efforts to reach new clients in markets further afield. We look forward to applying our expertise to support this client in achieving their development goals."

For more information about Physiomics and its services, please visit www.physiomics.co.uk.

Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.